Physician

Jamal Joudeh, MD

According to 2025 Medicare claims, Jamal Joudeh, MD (NPI: 1922214352) practices hematology/oncology in the Pensacola-Ferry Pass-Brent, FL market, with the plurality of this provider's patient population coming from Escambia, FL. This provider's primary affiliated billing organization is WOODLANDS MEDICAL SPECIALISTS P A (NPI: 1225274772; TIN: 261802830) and primary practice location at 32503-2339. Joudeh is affiliated with the Aledade 154 FL GA MSSP Enhanced (ACO ID: A5357), participating under the MSSP model.

Joudeh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,359 traditional Medicare patients, billed 258,077 HCPCS/CPT codes, and received $4,508,999 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,729 prescription claims across 297 beneficiaries totaling $2,737,034 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 35 claims. Open Payments data shows 52 records totaling $1,198. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $948,877 to $4,508,999. Similarly, Part D prescription costs have risen steadily, from $1,265,829 to $2,737,034. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,106	72,772	$948,877
2016	1,141	133,872	$1,593,002
2017	1,159	162,137	$1,680,726
2018	1,402	218,387	$2,572,995
2019	1,255	237,186	$2,995,747
2020	1,076	230,477	$3,355,004
2021	1,124	238,068	$4,006,223
2022	1,006	245,481	$3,651,667
2023	1,040	230,798	$3,892,753
2024	1,359	258,077	$4,508,999

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	256	1,325	$1,265,829
2016	273	1,745	$1,738,312
2017	207	1,309	$1,482,360
2018	215	1,453	$2,101,885
2019	228	1,516	$2,220,128
2020	219	1,438	$1,995,342
2021	209	1,405	$2,409,605
2022	216	1,442	$2,248,751
2023	240	1,540	$2,300,390
2024	297	1,729	$2,737,034

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	88	$16,038
2017	N/R	39	$1,317
2018	N/R	15	$4,907
2019	N/R	29	$3,164
2020	N/R	50	$4,693
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	11	$6,528
2024	N/R	35	$1,175

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	292	292	$120
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	846	1,980	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	203	217	$63
96375	Injection of additional new drug or substance into vein	158	639	$11
96372	Injection of drug or substance under skin or into muscle	146	381	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	37	1,036	$602,164
Lenalidomide	Lenalidomide	46	1,204	$487,667
Pomalyst	Pomalidomide	12	336	$280,767
Revlimid	Lenalidomide	14	392	$247,619
Ibrance	Palbociclib	14	392	$187,062

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$874
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	52	$1,198	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jamal Joudeh, MD?

Tedicare shows public-source Medicare data for Jamal Joudeh, MD (NPI 1922214352), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jamal Joudeh, MD have ACO affiliation data?

Jamal Joudeh, MD is shown with ACO affiliation data for Aledade 154 FL GA MSSP Enhanced (MSSP, ACO ID A5357).

What billing organization is linked to Jamal Joudeh, MD?

Jamal Joudeh, MD is linked to WOODLANDS MEDICAL SPECIALISTS P A (billing NPI 1225274772) in the available physician profile data.

Does Jamal Joudeh, MD have Open Payments data?

Jamal Joudeh, MD has 52 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.